Timeline
REGN3479
A Regeneron-developed monoclonal antibody targeting Bundibugyo ebolavirus, now in the first authorised Bundibugyo treatment trial alongside MBP134.
3 of 3 entries (3 events, 0 interactions)
Filters
#13 19 Aug
Mentioned in: 70,000 Ervebo doses, 20,000 as a trial
Pandemics and Biosecurity#11 16 Jul
Africa CDC: true cases up to 4x tally
Pandemics and Biosecurity#7 12 Jun